J Cancer 2017; 8(13):2487-2491. doi:10.7150/jca.18824 This issue Cite

Research Paper

Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma

Ming Bai, Hailin Zhang, Loubin Si, Nanze Yu, Ang Zeng, Ru Zhao

Department of Plastic and Reconstructive Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

Citation:
Bai M, Zhang H, Si L, Yu N, Zeng A, Zhao R. Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma. J Cancer 2017; 8(13):2487-2491. doi:10.7150/jca.18824. https://www.jcancer.org/v08p2487.htm
Other styles

File import instruction

Abstract

Aberrant expression of microRNAs (miRNAs) are believed to play a central role in the initiation and development of cancer. The aim of our study was to determine the clinical significance of serum miR-10b in melanoma. A total of 85 and 30 serum samples were obtained from patients with melanoma and healthy volunteers respectively. qRT-PCR was performed to evaluate the expression level of miR-10b in the melanoma cell lines and the serum samples from the participants. Then the clinical significance of serum miR-10b was further determined. Our results showed that the expression level of miR-10b was significantly increased in metastasis melanoma cells and melanoma patients compared to their respective controls. In addition, serum miR-10b expression level was able to discriminate melanoma patients from healthy volunteers as well differentiate melanoma patients at different clinical stage with high accuracy. Moreover, upregulation of serum miR-10b was positively associated with enhanced lymph node metastasis, advanced clinical stage and a shortened survival rate. Finally serum miR-10b was an independent prognostic factor for melanoma. Collectively, our study suggests that serum miR-10b level is upregulated in melanoma and associated with poor prognosis. It may be used as a potential prognostic biomarker for melanoma.

Keywords: Serum, miR-10b, melanoma, Prognosis.


Citation styles

APA
Bai, M., Zhang, H., Si, L., Yu, N., Zeng, A., Zhao, R. (2017). Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma. Journal of Cancer, 8(13), 2487-2491. https://doi.org/10.7150/jca.18824.

ACS
Bai, M.; Zhang, H.; Si, L.; Yu, N.; Zeng, A.; Zhao, R. Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma. J. Cancer 2017, 8 (13), 2487-2491. DOI: 10.7150/jca.18824.

NLM
Bai M, Zhang H, Si L, Yu N, Zeng A, Zhao R. Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma. J Cancer 2017; 8(13):2487-2491. doi:10.7150/jca.18824. https://www.jcancer.org/v08p2487.htm

CSE
Bai M, Zhang H, Si L, Yu N, Zeng A, Zhao R. 2017. Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma. J Cancer. 8(13):2487-2491.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image